Silk Road Medical, which sells medical devices to treat carotid artery disease, announced terms for its IPO on Monday.
The Sunnyvale, CA-based company plans to raise $75 million by offering 4.7 million shares at a price range of $15 to $17. Insiders intend to purchase $15 million worth of shares in the offering (20% of the deal). At the midpoint of the proposed range, Silk Road Medical would command a fully diluted market value of $513 million.
Silk Road Medical was founded in 2007 and booked $35 million in sales for the 12 months ended December 31, 2018. It plans to list on the Nasdaq under the symbol SILK. J.P. Morgan and BofA Merrill Lynch are the joint bookrunners on the deal. It is expected to price during the week of April 1, 2019.
Read More: https://www.nasdaq.com/article/carotid-artery-device-maker-silk-road-medical-sets-terms-for-75-million-ipo-cm1119264
Via: MedTech Dive
Silk Road Medical, which sells medical devices used in TCAR for the treatment of carotid artery disease, filed on Monday with the SEC to raise up to $86 million in an initial public offering.
Tepha Inc. Announces Initiation of Clinical Evaluation of P4HB™ Regenerative Scaffold for Stress Urinary Incontinence
Via: PR Newswire
LEXINGTON, Mass., Feb. 27, 2019 /PRNewswire/ -- Tepha Inc. announced today the initiation of a pilot clinical evaluation of the Company's P4HB regenerative polymer scaffold for the surgical treatment of stress urinary incontinence (SUI). The study was initiated in Cape Town, South Africa in partnership with the Pelvic Floor Foundation of South Africa ("PFFSA") and the University of Cape Town. The first procedures were performed by co-principal investigators, Dr. Stephen Jefferyof the University of Cape Town and Professor Jan-Paul Roovers of the Academic Medical Center, Amsterdam, The Netherlands. The Cape Town SUI study represents the first clinical application of Tepha's P4HB polymer technology in the field of urogynecology. Based in Lexington, MA, Tepha is the pioneer developer and exclusive supplier of the P4HB polymer for medical applications that include hernia repair, plastic surgery, tendon & ligament repair, and wound closure.
After winding down its consumer-oriented operations last July, mental health startup Lantern has partnered with larger mental health providers to license its IP. In addition to licensing its IP to Omada Health, Lantern has licensed its tech to Spring Health, Ginger and two others.
1NEWSISET 2019Surmounting Minor Stroke: New Devices, TCAR Aim to Cut Risk of Carotid Artery Stenting
Embolic protection, new stents, and TCAR are narrowing the gap between CAS and CEA, but medical therapy could still hold its own in CREST-2.
Dr. Michael Aragon and Stacey Porter Bring Wealth of Clinical and Organizational Expertise During Time of Company Grow
A Silicon Valley startup that pioneered a new way to fight diabetes is tackling depression after its CEO noticed a disturbing trend
Via: Business Insider
When Sean Duffy, the cofounder and CEO of a digital-health startup called Omada Health, took his first look at the results of his new diabetes-treatment program, he noticed a disturbing trend.
Blue Cross Blue Shield of Massachusetts Adds Two New Digital Health Solutions for Large Self-insured Clients
Via: PR Newswire
BOSTON, Jan. 8, 2019 /PRNewswire/ -- Blue Cross Blue Shield of Massachusetts (Blue Cross) recently added two new digital health solutions to its Emerging Solutions portfolio—Robin Care for cancer support and Hinge Health for musculoskeletal conditions such as back and knee pain.
Transcarotid artery revascularization with a neuroprotection system was associated with a low rate of stroke in patients with carotid artery stenosis, according to 1-year results of the ROADSTER trial.